Overview

A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) and certain of the Company’s current senior executive officers (collectively, “Defendants”) alleging violations of the federal securities laws. The Company’s common stock traded on the NASDAQ Stock Market under the symbol “IOVA.”

The Iovance class action lawsuit was brought on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024, and May 8, 2025, both dates inclusive (the “Class Period”).

Iovance is a commercial-stage biopharmaceutical company that develops and commercializes cell therapies to treat metastatic melanoma and other solid tumor cancers. The Company’s key product, Amtagvi®, is an autologous T cell immunotherapy to treat adults with unresectable or metastatic melanoma. Iovance also distributes Proleukin, an interleukin-2 product used in Amtagvi®’s treatment regimen. The treatments are conducted at authorized treatment centers (“ATCs”) in the United States, with regulatory approvals anticipated in both the United Kingdom and Canada in 2025.

The Iovance class action lawsuit alleges that Defendants, throughout the Class Period, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) new ATCs were experiencing longer timelines to begin treating patients with Amtagvi®; (ii) the Company’s sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi®, leading to higher patient drop-offs; (iii) as a result, the Company was facing higher costs and lower revenue because ATCs could not keep pace with manufactured product; and (iv) that, because of the foregoing, Defendants’ positive statements about Iovance’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

*          *          *

If you purchased or otherwise acquired Iovance securities between May 9, 2024, and May 8, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as lead plaintiff in the Iovance class action lawsuit is July 14, 2025